PSEUDOTYPED REPORTER VIRUS PARTICLES
Virology reagents for neutralization assays: ideal for therapeutic antibody and vaccine development
Reporter Virus Particles (RVPs): Pseudoviruses for Safe Neutralization Data

- Safe in a BSL-2 environment
- Ready-to-use pseudotyped viruses
- Quantitative (luciferase) or fluorescent (GFP) read-out
- Quality-controlled critical reagents based on 20+ years of virology expertise
“SARS-CoV-2 RVPs really helped us a lot since we did not have much previous expertise in SARS. The user meetings were especially helpful.”
Product Offerings: The Most Extensive Catalog of Reporter Virus Particles

Learn more about our most popular products:
> SARS-CoV-2 variant Reporter Virus Particles
> Influenza Reporter Virus Particles
> Filovirus Reporter Virus Particles
> Dengue and Zika RVP case study
Using RVPs in Your Research: Scientific & Regulatory Information
The Integral Advantage: 20+Years of Virology Experience
Deep expertise in virology is at the core of Integral Molecular’s 20-year history, and we have co-authored over 70 peer-reviewed virology publications in journals including Cell, Science and Nature. With the support of NIAID, scientists at Integral Molecular have been on the forefront of combatting viral epidemics including COVID-19, Zika, Ebola, and Chikungunya. Meet our team.
Trusted by 100+ Laboratories for R&D and Clinical Trials

Case Studies & Publications: See how our customers have used RVPs
Publications Establishing RVPs as a Critical Reagent
Frequently Asked Questions
Integral Molecular offers many vaccine development solutions including the production of reporter viruses, epitope mapping on viral targets, protein engineering for vaccine discovery, and antibody discovery against viral targets.
Yes. We can produce large lots of RVPs to accommodate screening 100s or 1000s of samples in sera neutralization assays without bridging studies.